Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM1 for WBRT-induced cognitive dysfunction in breast cancer
NCT04395339Phase 3Terminated
- Sponsor
- Sun Yat-sen University
- Start
- May 2020
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of monosialotetrahexosylganglioside in cognitive impairment, sponsored by Sun Yat-sen University. Started May 2020; status: terminated.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT04395339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04395339.